sipuleucel-T Injectable Product

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
051020082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Multiple immunotherapy platforms have been investigated for prostate cancer, but sipuleucel-T still remains the sole approved… (More)
Is this relevant?
Review
2016
Review
2016
New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2015
Review
2015
PURPOSE Antitumor activity of cancer immunotherapies may elicit immune responses to nontargeted (secondary) tumor antigens, or… (More)
Is this relevant?
Review
2015
Review
2015
Approved by the US Food and Drug Administration (FDA) in 2010, sipuleucel-T (Provenge®) was the first ‘personalized’ cancer… (More)
Is this relevant?
Review
2015
Review
2015
Prostate cancer remains highly prevalent and has a poor clinical outcome once metastatic. Sipuleucel-T is an autologous cellular… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2015
Review
2015
The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a… (More)
Is this relevant?
Review
2014
Review
2014
The objective is to examine the cost-utility of sipuleucel-T immunotherapy in asymptomatic or minimally symptomatic castration… (More)
Is this relevant?
Review
2012
Review
2012
UNLABELLED Sipuleucel-T is known to be very well tolerated and to prolong overall survival, but not progression-free survival… (More)
Is this relevant?
Review
2011
Review
2011
Sipuleucel-T is an autologous active cellular immunotherapy used in the treatment of men with asymptomatic or minimally… (More)
  • table I
Is this relevant?
Review
2011
Review
2011
Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed… (More)
Is this relevant?